<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945604</url>
  </required_header>
  <id_info>
    <org_study_id>FZPL-Ib-105</org_study_id>
    <nct_id>NCT03945604</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC</brief_title>
  <official_title>A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib and Fluzoparib in Subjects With Recurrent and Metastatic Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the tolerability, safety and efficacy of SHR-1210 in
      combination with Apatinib and Fluzoparib in subjects with recurrent and metastatic triple
      negative breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug: SHR-1210 + Apatinib +Fluzoparib SHR-1210 will be administered as an intravenous
      infusion, Apatinib tablets will be given orally, Fluzoparib capsule will be given orally 28
      days per cycle, until disease progression or unacceptable toxicity.

      Treatment group ： PD-1 antibody SHR-1210 combination with aptinib and fluzoparib
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">August 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>First cycle (28 days)</time_frame>
    <description>Dose Limiting Toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>from the first drug administration to within 90 days for the last SHR-1210 dose</time_frame>
    <description>AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 12 months (approx) from the start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>up to 12 months (approx) from the start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>up to 12 months (approx) from the start of treatment</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free-Survival</measure>
    <time_frame>up to 12 months (approx) from the start of treatment</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-months overall survival rate</measure>
    <time_frame>From the start of treatment to 1 year</time_frame>
    <description>12-months overall survival rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1210 + Apatinib +Fluzoparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210 + Apatinib +Fluzoparib</intervention_name>
    <description>SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.</description>
    <arm_group_label>SHR-1210 + Apatinib +Fluzoparib</arm_group_label>
    <other_name>Treatment group ： PD-1 antibody SHR-1210 combination with aptinib and fluzoparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed the informed consent.

          -  Female aged ≥18 years old.

          -  Histologically diagnosed patients with recurrent and metastatic triple negative breast
             cancer.

          -  No more than 2-line chemotherapy failed at the stage of recurrence and metastasis .

          -  Patients who have been treated with platinum-based regimen at the stage of
             recurrence/metastasis need non-disease progression (non-pd)during treatment

          -  At least one measuring lesion that comfirmed by RECIST v1.1 standard.

          -  The patients can swallow pills.

          -  Have a life expectancy of at least 12 weeks.

          -  The functions of vital organs meet protocal requirements.

        Exclusion Criteria:

          -  Subjects had any history of active autoimmune disease .

          -  Subjects had previously been treated with anti-PD-1 and PD-L1 antibodies, or was known
             to be allergic to antibody drugs, or had previously been treated with apatinib, or had
             previously been treated with PARP inhibitors.

          -  Subjects have untreated central nervous system metastasis.

          -  History of hypertension and antihypertensive medications are not well controlled.

          -  Some clinical symptoms or diseases of the heart that are not well controlled.

          -  History of immunodeficiency including HIV-positive.

          -  Subjects had active infections.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>only female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huiping Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hosptial</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zongfei Zongfei Dai, master</last_name>
    <phone>18616240775</phone>
    <email>zongfeidai@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Quanren Wang, PhD</last_name>
    <phone>18036618570</phone>
    <email>wangquanren@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hosptial</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huiping Li, MD</last_name>
      <email>huipingli2012@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

